Capital Raising


Xite Holdings Ltd

Privately owned lottery











Investment Highlights

Unique alphabet-based lottery concept with a pending patent

Exclusive rights of the Alphabet Lottery IP allow the Company to license rights of use or commercial exploitation to any other approved company

Strategic partnership announced with SCCG Management for Global distribution

Company Overview

xite loteries

Unique lottery product for global audience

Xite’s signature product, the AZ Billions Lottery™, is a unique alphabet-based lottery concept with a pending patent. They believe this is the first new lottery concept to be launched into the world Lottery market since Powerball in the early 1990’s.

As owners of Alphabet Lottery IP Xite can license rights of use or commercial exploitation to any other company or person approved by the Company. Licences drive brand awareness and increase overall revenues, reducing risk in an array of formats, images, and types, each with the potential to set the odds for that game.

A scalable business where other products (including scratch card lottery, online, real money mainstream lotteries and social gaming) can be added to the product mix to complement the business, under the same gaming license.

All licences & corporate structures are in place

Much of the challenging work is complete with the creation of the AZ Billions Lottery™, the establishment of their licensed subsidiary (AZB Games NV in Curacao that holds the gaming licence in the Netherlands Antilles) along with a subsidiary in Cyprus, providing merchant facilities in Europe, are complete and ready for a launch.

Funds will be used to finance the launch of the business by strengthening the marketing, IT, operations, and other corporate services on the journey to profitability and beyond.

Corporate Structure

ResolutionRx Ltd was formed in Australia in January 2023 by RespireRx as an unlisted public company. RespireRx Pharmaceuticals Inc. (US OTC: RSPI) is in the process of contributing, via sublicense and license with ResolutionRx, its cannabinoid drug development program subject to certain liabilities.

ResolutionRx is engaging in the R&D associated with that program, initially for the development of a new formulation of dronabinol for use in Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnoea (“OSA”).

The current total budget for that program over the next several years is approximately A$24.8M, most, but not all of which is expected to be eligible for the R&D tax refund expected to be 43.5%.

Strategic Partners

SCCG Management LLC


Agile Underwriting Services

Fast Offshore

Transaction Overview

The offer aims to raise up to A$5.5M with the issuance of up to 500,000 shares at an offer price of A$0.10 per share.

This offer is only available to those that qualify as sophisticated investors under s708 Corporations Act 2001 investors.

Minimum individual investment of A$25,000

The pre-money valuation of approximately A$55M

Use of funds




Operating Costs


Corporate Costs



General Disclaimer

The content on this site is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security and is not warranted to be correct, complete or accurate. This site is intended for Accredited/Sophisticated/Wholesale investors only. By continuing with an investment, you are self-accrediting that you so qualify. To the extent permitted by law, neither PrimaryMarkets, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment opportunities on this site and any statements made about them by their issuers are not vetted or verified by PrimaryMarkets. Investing in securities in private or unlisted companies and Funds is speculative and involves a high degree of risk. The investor must be prepared to withstand a total loss of their investment. We strongly encourage the investor to seek independent financial, professional or investment advice before investing in securities. The presence of an investment opportunities on this site should not be interpreted as an implied endorsement of it by PrimaryMarkets. Some content provided may constitute a summary or extract of another document. Past performance does not necessarily indicate future performance. The content on this site was current as at date of initial publication but may not be current as at the date of your viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.

Want to learn more?

Fill in the expression of interest form below